ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RGNT vs HSCS // 10Y YIELD & FRED MACRO BETA

Regentis Biomaterials Ltd. (NYSE) VS. HeartSciences Inc. (NASDAQ) • 15-METRIC TALLY: RGNT 0 — HSCS 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGNT VS. HSCS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RGNT HSCS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 59.10% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -14.39% — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -0.70% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 2/9 -1.00 HSCS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 38.6 47.8 -9.20 HSCS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $9.6M $16.0M -$6.4M HSCS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RGNT REV HSCS REV RGNT GROSS % HSCS GROSS % RGNT FCF HSCS FCF
FY 2025 $19.5M $4.3K — 59.1% -$1.4M -$7.4M
FY 2024 $2.6M $4.3K — 56.8% -$641.0K -$7.4M
FY 2023 $5.4M $18.6K — — -$1.2M -$6.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGNT // BETA —
HSCS // BETA —